Efficacy of a ketogenic diet in resistant myoclono-astatic epilepsy: A French multicenter retrospective study

Elodie Stenger1, Mickael Schaeffer1, Claude Cances2

  • 1Hôpital Universitaire de Strasbourg, Centre de Référence des Epilepsies Rares, France.

Epilepsy Research
|March 9, 2017
PubMed

Insights

Early ketogenic diet (KD) for myoclono-astatic epilepsy (MAE) shows significant seizure reduction and remission. This treatment also leads to better cognitive outcomes in children with drug-resistant epilepsy.

Area of Science:

  • Epilepsy research
  • Pediatric neurology
  • Ketogenic diet therapy

Background:

  • Myoclono-astatic epilepsy (MAE) is a severe form of childhood epilepsy.
  • Drug-resistant epilepsy often requires alternative treatment strategies.
  • Ketogenic diet (KD) has shown promise in managing refractory epilepsy.

Purpose of the Study:

  • To evaluate the efficacy of early ketogenic diet (KD) introduction in children with drug-resistant myoclono-astatic epilepsy (MAE).
  • To assess the impact of KD on seizure control, epilepsy, and developmental outcomes.
  • To determine if early KD intervention correlates with improved cognitive function.

Main Methods:

  • A multicenter study included 50 children with severe MAE treated with KD.
  • Seizure frequency and EEG were monitored before KD and at 2, 6 months, and during follow-up.
  • Developmental outcomes were assessed during the last follow-up.

Main Results:

  • After 6 months, 54% of patients achieved seizure freedom, and 86% had >70% seizure reduction within 2 months.
  • Early KD treatment (after 4 AEDs failed) showed a clear benefit in 44% of patients.
  • Earlier KD initiation (after 3 AEDs failed) correlated with better cognitive outcomes, and 50% of patients had normal development.

Conclusions:

  • Early introduction of KD in resistant MAE provides a persistent anticonvulsant effect.
  • KD treatment leads to long-term seizure remission and improved developmental outcomes.
  • Timely KD intervention is crucial for enhancing cognitive function in pediatric epilepsy patients.
Abstract

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
873
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K